IDO-IN-8 (NLG-1487) (Synonyms: NLG-1487) |
| Catalog No.GC34139 |
IDO-IN-8 (NLG-1487) (NLG-1487) est un inhibiteur d'indoleamine 2,3-dioxygénase (IDO) extrait du brevet WO WO2012142237A1, composé 1487, a une IC50 de 1-10 μM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1402837-77-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC50 of 1-10 μM.
IDO-IN-8 (Compound 1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor with an IC50 of 1-10 μM (this is the concentration of IDO-IN-8 at which inhibits 50% of enzymatic activity using recombinant human IDO)[1].
[1]. Mautino, et al. Preparation of fused imidazole derivatives as IDO inhibitors. From PCT Int. Appl. (2012), 20121018.
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *